Business

Easton Pharmaceuticals Moves to Directly Negotiate Exclusive Agreement With Private Medical Marijuana Grower in Canada as a Result of Galileo Life Science's Actions Toward Its Previously Executed Option and Purchase Agreement; Provides Formal Action Respo

Easton Pharmaceuticals Moves to Directly Negotiate Exclusive Agreement With Private Medical Marijuana Grower in Canada as a Result of Galileo Life Science's Actions Toward Its Previously Executed Option and Purchase Agreement; Provides Formal Action Respo.

articleEaston Pharmaceuticals IncJune 17, 20155/company/easton-pharmaceutica/news/easton-pharmaceuticals-moves-to-directly-negotiate-exclusive-agreement-with-private-medical-marijuana-grower-in-canada-as-a-result-of-galileo-life-sciences-actions-toward-its-previously-executed-option-and-purchase-agreement-provides-formal-action-respo
Easton Pharmaceuticals Moves to Directly Negotiate Exclusive Agreement With Private Medical Marijuana Grower in Canada as a Result of Galileo Life Science's Actions Toward Its Previously Executed Option and Purchase Agreement; Provides Formal Action Respo

About this update from Easton Pharmaceuticals Inc

[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Moves to Directly Negotiate Exclusive Agreement With Private Medical Marijuana Grower in Canada as a Result of Galileo Life Science's Actions Toward Its Previously Executed Option and Purchase Agreement; Provides Formal Action Response\n \n \nEaston Pharmaceuticals Moves to Directly Negotiate Exclusive Agreement With Private Medical Marijuana Grower in Canada as a Result of Galileo Life Science's Actions Toward Its Previously Executed Option and Purchase Agreement; Provides Formal Action Response\n \n TORONTO, ON--(Marketwired - Jun 17, 2015) - Easton Pharmaceuticals (OTC PINK: EAPH), a specialty pharmaceutical company involved in various sectors and industries, including medical marijuana, who designs, develops, and markets a premium array of topically-delivered therapeutic products, healthcare drugs and other products in different stages of development, provides formal response to Galileo Life Sciences (formerly MDRM Canada) and its Canadian Medical Marijuana intentions.\n As per official notice being received by Galileo Life Sciences (formerly MDRM) on June 16th and public disclosure by Galileo, Easton Pharmaceuticals makes formal response to the erroneous cancellation of Easton's option and purchase agreement executed in June of 2014 and releases the following statement:\n As a result of notice received from Galileo Life Sciences (formerly MDRM) that it has erroneously and without just cause canceled Easton's option and purchase agreement executed in June of 2014 which included a cash payment, Easton Pharmaceuticals (the \"Company\") has formulated an action plan commencing with Easton immediately moving forward with making direct contact to negotiate its own agreement with the private Ontario based medical marijuana grower who has received a letter to build from Health Canada.\n Easton Pharmaceuticals (the \"Company\") is steadfast with its belief that its option and purchase agreement signed in June of 2014 with Galileo Life Sciences (formerly MDRM) remains in full force and will take what actions are necessary to enforce this. Easton believes MDRM's actions may be as a result of the private Canadian Medical Marijuana grower having moved closer and to the next level in its application process to obtain an MMPR growers license with health Canada. Contrary to Galileo's statements, Easton maint...

More updates from Easton Pharmaceuticals Inc